Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Comparative effects of urocortins and stresscopin on cardiac myocyte contractility.

Makarewich CA, Troupes CD, Schumacher SM, Gross P, Koch WJ, Crandall DL, Houser SR.

J Mol Cell Cardiol. 2015 Sep;86:179-86. doi: 10.1016/j.yjmcc.2015.07.023. Epub 2015 Jul 29.

2.

Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.

Crombie AL, Antrilli TM, Campbell BA, Crandall DL, Failli AA, He Y, Kern JC, Moore WJ, Nogle LM, Trybulski EJ.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3742-5. doi: 10.1016/j.bmcl.2010.04.068. Epub 2010 Apr 21.

PMID:
20471258
3.

Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury.

Abderrahmani R, Fran├žois A, Buard V, Benderitter M, Sabourin JC, Crandall DL, Milliat F.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):942-8. doi: 10.1016/j.ijrobp.2009.01.077.

PMID:
19480973
4.

Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis.

Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, Crandall DL.

J Thromb Haemost. 2008 Sep;6(9):1558-64. doi: 10.1111/j.1538-7836.2008.03063.x. Epub 2008 Jul 4.

5.

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105. Epub 2008 Jun 16.

6.

Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.

Baxi S, Crandall DL, Meier TR, Wrobleski S, Hawley A, Farris D, Elokdah H, Sigler R, Schaub RG, Wakefield T, Myers D.

Thromb Haemost. 2008 Apr;99(4):749-58. doi: 10.1160/TH07-11-0669.

PMID:
18392333
7.

p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine.

Deng X, Lu J, Lehman-McKeeman LD, Malle E, Crandall DL, Ganey PE, Roth RA.

J Pharmacol Exp Ther. 2008 Jul;326(1):144-52. doi: 10.1124/jpet.108.137497. Epub 2008 Apr 4.

8.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

9.

Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action.

Gardell SJ, Krueger JA, Antrilli TA, Elokdah H, Mayer S, Orcutt SJ, Crandall DL, Vlasuk GP.

Mol Pharmacol. 2007 Oct;72(4):897-906. Epub 2007 Jul 10.

10.

GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P.

Br J Pharmacol. 2007 Jun;151(4):450-6. Epub 2007 Apr 10.

11.

Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.

Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, Crandall DL, Lawrence DA.

J Biol Chem. 2007 Mar 23;282(12):9288-96. Epub 2007 Feb 2.

12.

Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.

Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA.

J Thromb Haemost. 2006 Dec;4(12):2710-5. Epub 2006 Oct 2.

13.

Modulation of adipose tissue development by pharmacological inhibition of PAI-1.

Crandall DL, Quinet EM, El Ayachi S, Hreha AL, Leik CE, Savio DA, Juhan-Vague I, Alessi MC.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2209-15. Epub 2006 Jul 6.

14.

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP.

Thromb Haemost. 2006 Mar;95(3):469-75.

PMID:
16525575
15.

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL.

J Pharmacol Exp Ther. 2006 Apr;317(1):236-43. Epub 2005 Dec 12.

16.

Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.

Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE.

Blood. 2006 Jan 1;107(1):132-4. Epub 2005 Sep 13.

17.

Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1.

Hu B, Jetter JW, Wrobel JE, Antrilli TM, Bauer JS, Di L, Polakowski S, Jain U, Crandall DL.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3514-8.

PMID:
15982877
18.

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.

J Pharmacol Exp Ther. 2005 Aug;314(2):710-6. Epub 2005 Apr 28.

19.

Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.

Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ.

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):365-71. Epub 2004 Dec 2.

20.

Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.

Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, Lawrence DA.

J Thromb Haemost. 2004 Aug;2(8):1422-8.

21.

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL.

J Med Chem. 2004 Jul 1;47(14):3491-4.

PMID:
15214776
22.

Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1.

Gopalsamy A, Kincaid SL, Ellingboe JW, Groeling TM, Antrilli TM, Krishnamurthy G, Aulabaugh A, Friedrichs GS, Crandall DL.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3477-80.

PMID:
15177456
23.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, Swillo RE.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):904-8.

PMID:
14623266
24.

Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.

Gorlatova NV, Elokdah H, Fan K, Crandall DL, Lawrence DA.

J Biol Chem. 2003 May 2;278(18):16329-35. Epub 2003 Feb 26.

25.

Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.

Elokdah HM, Friedrichs GS, Chai SY, Harrison BL, Primeau J, Chlenov M, Crandall DL.

Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.

PMID:
12113820
26.

Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1.

Crandall DL, Groeling TM, Busler DE, Antrilli TM.

Biochem Biophys Res Commun. 2000 Dec 29;279(3):984-8.

PMID:
11162462
27.

Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1.

Crandall DL, Busler DE, McHendry-Rinde B, Groeling TM, Kral JG.

J Clin Endocrinol Metab. 2000 Jul;85(7):2609-14.

PMID:
10902815
28.

Development of a human adipocyte synthetic polymer scaffold.

Kral JG, Crandall DL.

Plast Reconstr Surg. 1999 Nov;104(6):1732-8.

PMID:
10541176
29.

Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes.

Crandall DL, Quinet EM, Morgan GA, Busler DE, McHendry-Rinde B, Kral JG.

J Clin Endocrinol Metab. 1999 Sep;84(9):3222-7.

PMID:
10487691
30.

PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon.

Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T, Crandall DL, Tickle S, Finney H, Yarranton G, Clowes AW.

Circulation. 1999 Feb 2;99(4):564-9.

31.

Angiotensin II receptors in human preadipocytes: role in cell cycle regulation.

Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG.

Endocrinology. 1999 Jan;140(1):154-8.

PMID:
9886820
32.

Identification of estrogen receptor beta RNA in human breast and abdominal subcutaneous adipose tissue.

Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG.

Biochem Biophys Res Commun. 1998 Jul 30;248(3):523-6.

PMID:
9703958
33.

A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives.

Crandall DL, Hausman GJ, Kral JG.

Microcirculation. 1997 Jun;4(2):211-32. Review.

PMID:
9219215
34.

Distribution of angiotensin II receptors in rat and human adipocytes.

Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG.

J Lipid Res. 1994 Aug;35(8):1378-85.

35.

Henry P. Bowditch's forgotten contributions to radiology.

Crandall DL, Barger AC.

AJR Am J Roentgenol. 1993 Nov;161(5):1105-8. No abstract available.

PMID:
8273619
36.

Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes.

Crandall DL, Herzlinger HE, Saunders BD, Zolotor RC, Feliciano L, Cervoni P.

Metabolism. 1993 Apr;42(4):511-5.

PMID:
8387626
37.

Transforming growth factor alpha and atrial natriuretic peptide in white adipose tissue depots in rats.

Crandall DL, Gordon G, Herzlinger HE, Saunders BD, Zolotor RC, Cervoni P, Kral JG.

Eur J Clin Invest. 1992 Oct;22(10):676-80.

PMID:
1333961
38.

Relationship of cardiac hemodynamic and biochemical adaptations to mortality during long-term aortic constriction.

Crandall DL, Goldstein BM, Ferraro GD, Cervoni P.

Proc Soc Exp Biol Med. 1991 Nov;198(2):747-53.

PMID:
1924410
39.

Hemodynamic and metabolic correlates in adipose tissue: pathophysiologic considerations.

Crandall DL, DiGirolamo M.

FASEB J. 1990 Feb 1;4(2):141-7. Review.

PMID:
2404816
40.

Effect of experimental obesity and subsequent weight reduction upon circulating atrial natriuretic peptide.

Crandall DL, Ferraro GD, Cervoni P.

Proc Soc Exp Biol Med. 1989 Sep;191(4):352-6.

PMID:
2528148
41.

Cardiovascular effects of intermittent drinking: assessment of a novel animal model of human alcoholism.

Crandall DL, Ferraro GD, Lozito RJ, Cervoni P, Clark LT.

J Hypertens. 1989 Aug;7(8):683-7.

PMID:
2809192
42.

Orr E. Reynolds Award. From Roxbury to Richmond: the military career of Henry P. Bowditch.

Crandall DL.

Physiologist. 1989 Aug;32(4):88-96. No abstract available.

PMID:
2682696
43.

Effect of varying concentrations of linoleic acid on alpha-adrenoceptor responses in spontaneously hypertensive rats.

Crandall DL, Goldstein BM, Lozito RJ, Lizzo FH, Cervoni P.

Prostaglandins Leukot Essent Fatty Acids. 1988 Aug;33(2):115-9.

PMID:
2845438
44.

Development of an animal model for investigating disparate myocardial effects of obesity and hypertension.

Crandall DL, Goldstein BM, Lizzo FH, Lozito RJ, Cervoni P.

J Appl Physiol (1985). 1988 Mar;64(3):1094-7.

PMID:
2966792
45.

Antilipolytic activity of viprostol, a transdermally active antihypertensive PGE2 analog.

Crandall DL, Vu V, Lizzo FH, Davis BA, Cervoni P.

Prostaglandins. 1987 May;33(5):767-73.

PMID:
2438724
46.

Assessment of animal models for investigating the cardiovascular adaptations to obesity.

Crandall DL, Cervoni P.

Pathol Immunopathol Res. 1987;6(4):284-300. Review.

PMID:
3329341
47.

Hemodynamics of obesity: influence of pattern of adipose tissue cellularity.

Crandall DL, Goldstein BM, Lizzo FH, Gabel RA, Cervoni P.

Am J Physiol. 1986 Aug;251(2 Pt 2):R314-9.

PMID:
3740313
48.

Myocardial adaptations to dietary sucrose in spontaneously hypertensive rats.

Crandall DL, Goldstein BM, Lizzo FH, Lozito RJ, Cervoni P.

Res Commun Chem Pathol Pharmacol. 1986 Aug;53(2):237-40.

PMID:
3020652
49.

Effects of glucose, insulin and epinephrine on lactate metabolism by isolated adipocytes.

Crandall DL, Francendese AA, DiGirolamo M.

Res Commun Chem Pathol Pharmacol. 1986 Jun;52(3):395-8.

PMID:
3526480
50.

Effect of contractile activity on rat skeletal muscle beta-adrenoceptor properties.

Fell RD, Lizzo FH, Cervoni P, Crandall DL.

Proc Soc Exp Biol Med. 1985 Dec;180(3):527-32.

PMID:
3001745

Supplemental Content

Loading ...
Support Center